Which therapy should be chosen for hard-to-treat RA?
A head-to-head study pits a second-generation JAK inhibitor against abatacept.
A head-to-head study pits a second-generation JAK inhibitor against abatacept.
Pilot trial of a device the size of a coffee bean shows it is well tolerated.
Long-term use is linked to raised risk of cardiac deaths, data show.
Study shows multiple joint tenderness contributes to poor hand function.
Pooled data from 13 studies shows better scores with combination therapy.
The long-term study indicates treating to autoantibody disappearance is not appropriate.
Rheumatology patients say trust in their doctor is the number one reason for adherence: study.
Expert calls for head-to-head comparisons with other therapies.
Real-world study finds some of the patients appear to have low disease activity.
The majority avoid pregnancy over fears they won't be able to care for their children, reveals survey.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.